Regulatory glossary

Clinical Hold: Grounds, Response, and the 30 Day Clock

A clinical hold is an FDA order suspending or restricting a clinical investigation under an IND. It is issued under 21 CFR 312.42, and it is the agency's most direct intervention short of terminating the IND.

A hold can arrive before you ever dose a patient. A proposed study placed on hold at the 30 day mark never starts.

Full and partial

A full hold stops the whole investigation. A partial hold restricts part of it: one arm, one dose level, one site, or enrolment of a particular population while the rest continues.

Partial holds are common and are often mistaken for a lesser problem. The response obligation is the same.

Grounds

For a Phase 1 study, 21 CFR 312.42(b)(1) allows a hold where:

• Subjects would be exposed to an unreasonable and significant risk of illness or injury.
• The investigators are not qualified by training and experience.
• The investigator brochure is misleading, erroneous or materially incomplete.
• The IND does not contain enough information to assess the risks.

Phase 2 and 3 studies carry an additional ground: a protocol clearly deficient in design to meet its stated objectives.

In practice the causes cluster. Insufficient nonclinical data and CMC deficiencies account for a large share of holds on initial INDs, which means the problem is frequently a gap in the file rather than a finding about the drug.

The written explanation

FDA imposes a hold by telephone or other rapid means, then must provide a written explanation of the basis. That letter is the specification for your response. Every issue it raises has to be answered.

The complete response

A complete response is one that addresses all issues in the hold letter. Not most. A partial answer does not start the clock; it produces another round of questions.

Practical points that shorten the cycle:

• Mark the cover letter "Clinical Hold Complete Response" in large bold type at the top, so it is routed as one.
• Answer the letter in its own order, issue by issue, so a reviewer can check off against their own document.
• Where you disagree, say so with data. A hold is a scientific dispute you are allowed to argue, unlike an administrative deadline.

Once FDA has your complete response, it works to 30 calendar days to reply in writing, either removing or maintaining the hold, with reasons.

What it costs beyond the delay

A hold on a lead programme is disclosable, and for a public company it usually is disclosed. It affects financing, partnering and the next round of trial planning. The regulatory work it creates lands on the same small team that is also running the study.

If the hold is CMC-driven, the fix often means new stability, new analytical method validation or a manufacturing change, and those have their own lead times that no amount of writing shortens.